Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPSV23 Effectiveness in Children with Type 1 Diabetes
NCT04481243Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Mayo Clinic. Primary endpoint: Immunoglobulin G (IgG) Antibodies at 6 months. Started Apr 2021; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04481243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481243.